University of Florida: Myelodysplastic Syndromes trials
The registry lists 10 Myelodysplastic Syndromes studies with University of Florida as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 4Phase 2 3Phase 3 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic SyndromesWithdrawnNCT03446638Not applicable
- iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AMLWithdrawnNCT03138395
- Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)TerminatedNCT03016130Phase 3
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)WithdrawnNCT02835794Phase 1/2
- iCare for Cancer PatientsTerminatedNCT02435550Not applicable
- Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
- A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSTerminatedNCT01085656Phase 1